TW200406402A - 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists - Google Patents

3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists Download PDF

Info

Publication number
TW200406402A
TW200406402A TW092109786A TW92109786A TW200406402A TW 200406402 A TW200406402 A TW 200406402A TW 092109786 A TW092109786 A TW 092109786A TW 92109786 A TW92109786 A TW 92109786A TW 200406402 A TW200406402 A TW 200406402A
Authority
TW
Taiwan
Prior art keywords
disease
pain
compound
pharmaceutically acceptable
compounds
Prior art date
Application number
TW092109786A
Other languages
English (en)
Chinese (zh)
Inventor
Mitsuhiro Kawamura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200406402A publication Critical patent/TW200406402A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092109786A 2002-04-26 2003-04-25 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists TW200406402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
TW200406402A true TW200406402A (en) 2004-05-01

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092109786A TW200406402A (en) 2002-04-26 2003-04-25 3,4-Dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists

Country Status (15)

Country Link
US (1) US6713490B2 (enExample)
EP (1) EP1499606B8 (enExample)
JP (1) JP2005524696A (enExample)
AR (1) AR039663A1 (enExample)
AT (1) ATE325117T1 (enExample)
AU (1) AU2003219398A1 (enExample)
BR (1) BR0309778A (enExample)
CA (1) CA2483636A1 (enExample)
DE (1) DE60305026T2 (enExample)
ES (1) ES2258716T3 (enExample)
MX (1) MXPA04010549A (enExample)
PA (1) PA8572601A1 (enExample)
TW (1) TW200406402A (enExample)
UY (1) UY27776A1 (enExample)
WO (1) WO2003091241A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
MXPA06003748A (es) * 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP1736474A4 (en) * 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
US20120077883A1 (en) * 2009-03-31 2012-03-29 De Barros Coelho Claudia Couto Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
ES2627541T3 (es) 2012-04-20 2017-07-28 Ucb Pharma, S.A. Métodos para tratar la enfermedad de Parkinson
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
RU2068414C1 (ru) 1990-05-10 1996-10-27 Пфайзер Инк. Производные индолона в виде рацемата или оптически активного изомера или их фармацевтически приемлемые аддитивные соли кислоты и кетопроизводные индолона
EP0666854B1 (en) 1992-10-30 1997-03-26 Pfizer Inc. Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol

Also Published As

Publication number Publication date
ES2258716T3 (es) 2006-09-01
EP1499606B8 (en) 2006-08-30
US20030216430A1 (en) 2003-11-20
MXPA04010549A (es) 2005-02-17
DE60305026T2 (de) 2006-10-12
JP2005524696A (ja) 2005-08-18
DE60305026D1 (de) 2006-06-08
EP1499606A1 (en) 2005-01-26
US6713490B2 (en) 2004-03-30
BR0309778A (pt) 2005-03-08
CA2483636A1 (en) 2003-11-06
EP1499606B1 (en) 2006-05-03
PA8572601A1 (es) 2004-12-16
AR039663A1 (es) 2005-03-02
UY27776A1 (es) 2003-11-28
WO2003091241A1 (en) 2003-11-06
ATE325117T1 (de) 2006-06-15
AU2003219398A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
CN104797555B (zh) N‑取代的苯甲酰胺及其使用方法
WO2016169504A1 (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
US9802945B2 (en) Imidazopyridazine derivatives as modulators of the GABAA receptor activity
CN105254557A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
CN108395452A (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
CN109071426A (zh) 取代的苯甲酰胺及其使用方法
US20040204409A1 (en) Bicyclic compounds as NR2B receptor antagonists
JP2017528503A (ja) 新規化合物αｖβ６インテグリンアンタゴニスト
JPH10279578A (ja) 新規なアリールピペリジン化合物、その製造法、及びそれらを含む医薬組成物
EP1499606B1 (en) 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
TW200902532A (en) Aza-pyridopyrimidinone derivatives
CN108601775A (zh) 阿片受体配体和细胞色素p450抑制剂的组合
CN114409658B (zh) 一种同时调节btk和ikzf3的双功能化合物
TW201206435A (en) Piperidinyl compound as a modulator of chemokine receptor activity
WO2017198180A1 (zh) 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
JP2007508288A (ja) 縮合ラクタム化合物
TW200927090A (en) Novel sulfamate compounds for medical use
EP3105207A1 (en) Gpr142 agonist compounds
CN110511173B (zh) 一种吲哚烷基哌嗪苯甲酰胺类化合物及其应用
CN116903571B (zh) 一种异黄酮化合物或其药物学上的盐的用途
CN116891447B (zh) 一类trpv1拮抗剂、制备方法及其在制备治疗疼痛药物中的应用
JPH11189585A (ja) ５−ｈｔ７受容体結合能を有するテトラヒドロベンズインドール誘導体
HK40065215B (en) Difunctional compound for simultaneously regulating btk and ikzf3
HK40065215A (en) Difunctional compound for simultaneously regulating btk and ikzf3
WO2025031459A9 (zh) 一种氮杂麦角林类衍生物、其药物组合物和其应用